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sured by the CartiLaps ELISA assay and corrected for urinary
creatinine levels. We used log(uCTX-II) to have approximately
normally distributed marker values.
The BL distribution of KL scores was (145,88,30,24,1) for KL 0-4.
Among the BL healthy knees (KL 0), 101 were non-progressors
at FU (KL 0) and 25 were progressors (KL > 0).
The prognostic ability was evaluated on whether the biomarker
BL values separated progressors from non-progressors with
MANOVA statistical signiﬁcance and by sample size (n) and
odds ratio (OR) for predicting progression.
An aggregate biomarkers was made by combining all biomark-
ers and the cartilage longevity marker by combining uCTX-II
with cartilage volume and homogeneity by linear discriminant
analysis. They were evaluated by repeated random sampling
of disjoint training and evaluation subsets to avoid performance
overestimation due to overtraining.
Results: The table lists p value for separating progressors from
non-progressors with the corresponding n and OR for each
biomarker. Only the compartment with best performance is listed
for the MRI markers. Also age and BMI predicted progression
(p<0.01) but not congruity and sex.
Prediction of Progression (evaluated by MANOVA p-value, sample size n, and
odds ratio OR)
Biomarker P-value n OR
JSW 0.5 – –
uCTX-II 0.004 71 6.7
Volume (MF.VC) 0.08 218 2.8
Area (MT.AC) 0.07 216 2.8
Thickness (MT.ThCtAB) 0.2 – –
Smoothness (MT.SmoC) 0.01 118 3.8
Homogeneity (MT.HomC) 0.002 69 4.9
Aggregate: All markers 0.001 50 6.3
Aggregate: Cartilage Longevity
(uCTX-II, Homogeneity, Volume) 0.00003 29 14.6
Conclusions: The results demonstrated that both biochemical
and MRI-based biomarkers were suitable prognostic biomarkers
while JSW appeared unsuited. The best individual biomarker
was uCTX-II requiring n 71 and offering OR 6.7. However, the
cartilage longevity marker combining uCTX-II, homogeneity and
volume had n 29 and OR 14.6. This prognostic marker may there-
fore provide much stronger study population selection - allowing
clinical studies to show the true effect of potential treatments.
Furthermore, the longevity marker is intuitively appealing since it
combines aspects of cartilage quantity (volume), quality (homo-
geneity), and breakdown (uCTX-II) - the natural components in
a comprehensive prognosis on expected cartilage life-span.
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Purpose: Cartilage turnover consists of both physiological and
pathological turnover. Until now, these processes have not been
separated due to lack of molecular tools. Today, it is still debated
which family of enzymes that are the major players of aggre-
can degradation under pathological conditions. Previously, we
have shown that early stage aggrecanase-mediated aggrecan
degradation was fully reversible after catabolic stimulation with
Tumor Necrosis Factor Alpha (TNFα) and Oncostatin M (OSM) in
combination, followed by anabolic treatment with Insulin Growth
Factor-I (IGF-I), whereas late stage MMP-mediated degradation
was irreversible. In this study, we further investigated the time-
dependent degradation proﬁle of proteoglycans in cartilage with
focus on MMP and aggrecanase activity and characterized these
different molecules.
Methods: Cartilage depletion was stimulated in bovine artic-
ular cartilage explants by TNFα (20ng/ml) and Oncostatin M
(OSM) (10ng/ml) treatment. Cartilage degradation was measured
by two independent immunoassays: MMP-mediated aggrecan
degradation and aggrecanase-mediated aggrecan degradation,
342FFGVG-G2 and 374ARGSVI-G2 respectively. Glycosaminogly-
cans (GAGs) were quantiﬁed by a colorimetric assay. Cell culture
supernatants were further investigated by western blots by mon-
oclonal antibody against the MMP-generated 342FFGVG neo-
epitope, or the aggrecanase-generated 374ARGSVI sequence.
Importantly because of the location of the fragments in aggre-
can, in theory, MMP-generated fragments cannot be generated
secondary to aggrecanase cleavage, but the aggrecanase site
may be generated after MMP cleavage.
Results: Cytokine stimulation resulted in early release of
aggrecanase-mediated cartilage degradation fragments at day
7, as quantiﬁed by 374ARGSVI-G2, which was increased ap-
proximately 723% and GAGs were similarly elevated by 206%.
The increases were apparent until day 11 where aggrecanase-
mediated aggrecan depletion was exhausted. In contrast, MMP-
mediated aggrecan degradation began at day 16 until the end
of the study-period, resulting in a ﬁnal increase of 1598% of
342FFGVG-G2 fragments. Western blot analysis showed high
molecular weight GAG-entailing 374ARGSVI fragments at day 7,
in contrast to low molecular weight non-glycolysated 342FFGVG
analytes at day 21. When digesting OSM/TNFα stimulated ex-
plants from day 21 in vitro with ADAMTS-4, we observed a 225%
increase in the (374ARGSVI-G2/342FFGVG-G2) ratio (P=0.04).
Conclusions: This study demonstrates that two distinct pools of
aggrecan molecules exist in the articular cartilage. Secondary,
in contrast to previous publications that MMP-processed aggre-
can can be further degraded by aggrecanases. The pool of
high-molecular weight aggrecan, susceptible for aggrecanase-
mediated degradation, may be associated with fully reversible
cartilage degradation. In contrast, low molecular weight aggre-
can, degraded by MMPs may be associated with irreversible
cartilage destruction. These data begin to provide a molecular
understanding of reversible and non-reversible cartilage turnover.
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Purpose: Degradation of type II collagen is one of the hallmarks
of cartilage damage in osteoarthritis (OA). Urinary biochemical
markers reﬂecting the degradation of the helical (Helix-II) and
C-telopeptide (CTX-II) regions of type II collagen have been
developed and levels of both markers have been shown to
be associated with more rapid radiological progression in OA.
However, urinary markers have limitations including relatively
high imprecision due to variable urine dilution and the need for
creatinine correction. In addition a precise sampling of urine is
often difﬁcult in elderly patients. To overcome these limitations it
is useful to obtain serum-based biochemical markers. The aim
of our study was to investigate the association between serum
